Hims & Hers Health Is Looking to Cash In on This Novo Nordisk Blunder

Hims & Hers Health (NYSE: HIMS) is a top telehealth stock that has been growing its business rapidly in recent years. And one of the ways it has done that is by expanding into new markets and reaching a broader range of customers.Recently, it's looking to take advantage of an opportunity that has opened up as a result of a costly mistake that drugmaker Novo Nordisk (NYSE: NVO) has made. After failing to pay a maintenance fee, the patent on semaglutide will run out in Canada as early as next year. And Hims & Hers is looking to capitalize on that.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool